Cargando…
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
Pancreatic ductal adenocarcinoma (PDAC) is currently the most deadly cancer. Although characterized by 5–20% of neoplastic cells in the highly fibrotic stroma, immunotherapy is not a valid option in PDAC treatment. As CXCR4-CXCL12 regulates tumor invasion and T-cell access and PD-1/PD-L1 controls im...
Autores principales: | D’Alterio, Crescenzo, Giardino, Alessandro, Scognamiglio, Giosuè, Butturini, Giovanni, Portella, Luigi, Guardascione, Giuseppe, Frigerio, Isabella, Montella, Marco, Gobbo, Stefano, Martignoni, Guido, Napolitano, Vincenzo, De Vita, Ferdinando, Tatangelo, Fabiana, Franco, Renato, Scala, Stefania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655815/ https://www.ncbi.nlm.nih.gov/pubmed/36359736 http://dx.doi.org/10.3390/cells11213340 |
Ejemplares similares
-
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR
por: Circelli, Luisa, et al.
Publicado: (2016) -
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
por: D’Alterio, Crescenzo, et al.
Publicado: (2019) -
CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells
por: Ieranò, Caterina, et al.
Publicado: (2019) -
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022) -
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
por: Neve Polimeno, Maria, et al.
Publicado: (2015)